News

1 to 9 of 33 results

UPDATE: Serono tops forecasts as EPS rockets 54%

01-11-2004

Posting third-quarter 2004 results which beat analysts' consensus forecasts, Switzerland-based Serono…

AlphaAvonexBiogen IdecFollitropin AlfaGonal-FInterferon beta-1aMitoxantrone for Injection ConcentrateNatalizumabNovantroneProlastinRebifTysabri

Serono sees 3rd-qtr net income leaps 47%

01-11-2004

Switzerland-based Serono SA, Europe's largest and the world's third biggest biotechnology firm, posted…

AlphaAvonexFollitropin AlfaGonal-FInterferon beta-1aMitoxantrone for Injection ConcentrateNovantroneProlastinRebif

Serono's 1st-qtr income rockets 76.4%

26-04-2004

Geneva, Switzerland-based Serono recorded net income of $106.1 million for the first quarter of 2004,…

AlphaAvonexEfalizumabFollitropin AlfaGenentechGonal-FInterferon beta-1aMitoxantrone for Injection ConcentrateNovantroneProlastinRaptivaRebifSaizenSomatropin Injection

Serono

05-05-2003

Switzerland-based Serono SA, Europe's largest biotechnology group,posted disappointing first-quarter…

AmgenAntihemophilic FactorAvonexCoagulation Factor VIIaEfalizumabFollitropin AlfaGenentechGonal-FInterferon beta-1aMitoxantrone for Injection ConcentrateNovantroneRaptivaRebifRecombinant

OSI in $55M deal to sell Serono's Novantrone

17-03-2003

OSI Pharmaceuticals has entered into an agreement to market Serono'santicancer drug Novantrone (mitoxantrone…

AmgenAmino AcidsAvonexInjectionInterferon beta-1aMitoxantrone for Injection ConcentrateNovantronePhysostigmine SalicylateRebif

Serono sees 15%-20% growth for 2003

10-02-2003

Switzerland's Serono SA posted full-year- 2002 revenues of $1.55billion, up 12.4% on the previous year,…

AmgenAnastrozoleArimidexAstraZenecaAvonexCladribineEfalizumabFollitropin AlfaGenentechGonal-FInterferon beta-1aIvaxLeustatinMitoxantrone for Injection ConcentrateNovantroneNystatinOralRaptivaRebif

1 to 9 of 33 results

Back to top